Characteristics of population after propensity score matching
| . | Without LVT (n = 127) . | With LVT (n = 127) . | P value . |
|---|---|---|---|
| Age, median (IQR), y | 58 (48-66) | 57 (49-65) | .46 |
| Sex | .12 | ||
| Female | 43 (33.9) | 55 (43.3) | |
| Male | 84 (66.1) | 72 (56.7) | |
| Histology | .07 | ||
| DLBCL | 94 (74.0) | 81 (63.8) | |
| PMBL | 7 (5.5) | 17 (13.4) | |
| tFL | 26 (20.5) | 29 (22.8) | |
| LDH | .12 | ||
| Normal | 65 (52.4) | 30 (41.1) | |
| Elevated | 59 (47.6) | 43 (58.9) | |
| Missing | 3 | 54 | |
| ECOG PS score | .72 | ||
| 0-1 | 108 (85.0) | 110 (86.6) | |
| >1 | 19 (15.0) | 17 (13.4) | |
| Stage | .99 | ||
| I-II | 39 (30.7) | 39 (30.7) | |
| III-IV | 88 (69.3) | 88 (69.3) | |
| Extranodal | .02 | ||
| No | 94 (74.6) | 77 (61.1) | |
| Yes | 32 (25.4) | 49 (38.9) | |
| Missing | 1 | 1 | |
| IPI | .50 | ||
| 0-1 | 32 (43.2) | 44 (34.9) | |
| 2-3 | 35 (47.3) | 69 (54.8) | |
| 4-5 | 7 (9.5) | 13 (10.3) | |
| Missing | 53 | 1 | |
| Bridging | .68 | ||
| No | 14 (11.1) | 16 (12.8) | |
| Yes | 112 (88.9) | 109 (87.2) | |
| Missing | 1 | 2 | |
| Previous ASCT | .76 | ||
| No | 100 (78.7) | 102 (80.3) | |
| Yes | 27 (21.3) | 25 (19.7) | |
| CAR-T therapy | .60 | ||
| axi-cel | 81 (63.8) | 85 (66.9) | |
| tisa-cel | 46 (36.2) | 42 (33.1) | |
| Previous lines | .008 | ||
| 1 | 16 (12.6) | 26 (20.5) | |
| 2 | 71 (55.9) | 81 (63.8) | |
| ≥3 | 40 (31.5) | 20 (15.7) | |
| Status before CAR-T therapy | .24 | ||
| CR-PR | 41 (32.3) | 50 (39.4) | |
| SD-PD | 86 (67.7) | 77 (60.6) | |
| CAR-HEMATOTOX | .17 | ||
| 0 | 17 (13.4) | 29 (22.8) | |
| 1 | 52 (40.9) | 48 (37.8) | |
| 2 | 26 (20.5) | 28 (22.0) | |
| 3 | 14 (11.0) | 13 (10.2) | |
| ≥4 | 18 (14.2) | 9 (7.1) | |
| mEASIX | 4.2 (2.1-6.1) | 2.7 (0.8-5.0) | <.001 |
| Missing | 28 | 7 |
| . | Without LVT (n = 127) . | With LVT (n = 127) . | P value . |
|---|---|---|---|
| Age, median (IQR), y | 58 (48-66) | 57 (49-65) | .46 |
| Sex | .12 | ||
| Female | 43 (33.9) | 55 (43.3) | |
| Male | 84 (66.1) | 72 (56.7) | |
| Histology | .07 | ||
| DLBCL | 94 (74.0) | 81 (63.8) | |
| PMBL | 7 (5.5) | 17 (13.4) | |
| tFL | 26 (20.5) | 29 (22.8) | |
| LDH | .12 | ||
| Normal | 65 (52.4) | 30 (41.1) | |
| Elevated | 59 (47.6) | 43 (58.9) | |
| Missing | 3 | 54 | |
| ECOG PS score | .72 | ||
| 0-1 | 108 (85.0) | 110 (86.6) | |
| >1 | 19 (15.0) | 17 (13.4) | |
| Stage | .99 | ||
| I-II | 39 (30.7) | 39 (30.7) | |
| III-IV | 88 (69.3) | 88 (69.3) | |
| Extranodal | .02 | ||
| No | 94 (74.6) | 77 (61.1) | |
| Yes | 32 (25.4) | 49 (38.9) | |
| Missing | 1 | 1 | |
| IPI | .50 | ||
| 0-1 | 32 (43.2) | 44 (34.9) | |
| 2-3 | 35 (47.3) | 69 (54.8) | |
| 4-5 | 7 (9.5) | 13 (10.3) | |
| Missing | 53 | 1 | |
| Bridging | .68 | ||
| No | 14 (11.1) | 16 (12.8) | |
| Yes | 112 (88.9) | 109 (87.2) | |
| Missing | 1 | 2 | |
| Previous ASCT | .76 | ||
| No | 100 (78.7) | 102 (80.3) | |
| Yes | 27 (21.3) | 25 (19.7) | |
| CAR-T therapy | .60 | ||
| axi-cel | 81 (63.8) | 85 (66.9) | |
| tisa-cel | 46 (36.2) | 42 (33.1) | |
| Previous lines | .008 | ||
| 1 | 16 (12.6) | 26 (20.5) | |
| 2 | 71 (55.9) | 81 (63.8) | |
| ≥3 | 40 (31.5) | 20 (15.7) | |
| Status before CAR-T therapy | .24 | ||
| CR-PR | 41 (32.3) | 50 (39.4) | |
| SD-PD | 86 (67.7) | 77 (60.6) | |
| CAR-HEMATOTOX | .17 | ||
| 0 | 17 (13.4) | 29 (22.8) | |
| 1 | 52 (40.9) | 48 (37.8) | |
| 2 | 26 (20.5) | 28 (22.0) | |
| 3 | 14 (11.0) | 13 (10.2) | |
| ≥4 | 18 (14.2) | 9 (7.1) | |
| mEASIX | 4.2 (2.1-6.1) | 2.7 (0.8-5.0) | <.001 |
| Missing | 28 | 7 |
Data are presented as n (%) unless otherwise specified.
ASCT, autologous hematopoietic stem cell transplantation; CR, complete response; DLBCL, diffuse LBCL; IPI, International Prognostic Index; IQR, interquartile range; LDH, lactate dehydrogenase; PD, progressive disease; PMBL, primary mediastinal BCL; PR, partial response; SD, stable disease; tFL, transformed follicular lymphoma; tisa-cel, tisagenlecleucel.